down arrow

Alnylam Pharmaceuticals, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02043Q1076
USD
294.06
5.88 (2.04%)

Jun 24

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

290.93303.22

52 Week

273.17495.31
Valuation
Technical
Day's Volume

CASH

369.79 k

Shareholding (Mar 2026)

FII

20.44%

Held by 421 FIIs

DII

77.85%

Held by 74 DIIs

Promoter

1.71%

Is Alnylam Pharmaceuticals, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Alnylam Pharmaceuticals has a mildly bullish technical trend, supported by monthly indicators and daily moving averages, despite some bearish signals in the weekly timeframe, and it has significantly outperformed the S&P 500 year-to-date and over the past three years.

As of 31 October 2025, the technical trend for Alnylam Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are mildly bearish, while the monthly MACD and KST are bullish. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, and daily moving averages are also mildly bullish. However, Dow Theory indicates a mildly bearish trend on both weekly and monthly bases. <BR><BR>In terms of performance, Alnylam has significantly outperformed the S&P 500 year-to-date with a return of 79.96% compared to 16.30%, and over the past three years, it has returned 96.31% versus the S&P 500's 76.66%. Overall, the current technical stance is mildly bullish, supported by the monthly indicators and daily moving averages, despite some bearish signals in the weekly timeframe.

View full answer

How big is Alnylam Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Alnylam Pharmaceuticals, Inc. has a market capitalization of $40.25 billion, with recent net sales of $2.35 billion and a net profit of -$269.70 million.

Market Cap: As of Jun 18, Alnylam Pharmaceuticals, Inc. has a market capitalization of 40,252.20 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Alnylam Pharmaceuticals, Inc. reported net sales of 2,348.11 million and a net profit of -269.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 67.09 million and total assets of 4,301.82 million.

View full answer

What does Alnylam Pharmaceuticals, Inc. do?

22-Jun-2025

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference therapeutics, with recent net sales of $594 million and a market cap of approximately $40.25 billion. The company is currently operating at a loss, with a net profit of -$57 million.

Overview: <BR>Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development, and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 594 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -57 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 40,252.20 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.21 <BR>Return on Equity: -42.12% <BR>Price to Book: 348.70<BR><BR>Contact Details: <BR>Address: 675 W Kendall St, CAMBRIDGE MA: 02142-1168 <BR>Tel: 1 617 5518200 <BR>Fax: 1 617 5518101 <BR>Website: https://www.alnylam.com/

View full answer

Who are in the management team of Alnylam Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Alnylam Pharmaceuticals, Inc. includes CEO Dr. John Maraganore and Independent Chairman Mr. Michael Bonney, along with several independent directors such as Dr. Margaret Hamburg and Dr. Steven Paul. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Alnylam Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Michael Bonney, Independent Chairman of the Board<BR>- Dr. John Maraganore, Chief Executive Officer and Director<BR>- Mr. Olivier Brandicourt, Director<BR>- Dr. Dennis Ausiello, Independent Director<BR>- Ms. Marsha Fanucci, Independent Director<BR>- Dr. Margaret Hamburg, Independent Director<BR>- Dr. Steven Paul, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

View full answer

Should I buy, sell or hold Alnylam Pharmaceuticals, Inc.?

22-Jun-2025

Compare Alnylam Pharmaceuticals, Inc. with Similar Stocks

Horizon Therapeutics PlcSeagen Inc.Zoetis, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Operating Profit of 80.71%, the company declared Outstanding results in Mar 26

  • The company has declared positive results for the last 3 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 712.9 MM
  • ROCE(HY) Highest at 96.94%
  • INVENTORY TURNOVER RATIO(HY) Highest at 10.99 times
2

With ROE of 45.14%, it has a attractive valuation with a 53.33 Price to Book Value

3

High Institutional Holdings at 100%

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 42,089 Million (Mid Cap)

stock-summary
P/E

118.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.21

stock-summary
Return on Equity

45.14%

stock-summary
Price to Book

53.33

Revenue and Profits:
Net Sales:
1,167 Million
(Quarterly Results - Mar 2026)
Net Profit:
206 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.54%
0%
-4.54%
6 Months
-26.61%
0%
-26.61%
1 Year
-9.52%
0%
-9.52%
2 Years
31.92%
0%
31.92%
3 Years
52.61%
0%
52.61%
4 Years
99.36%
0%
99.36%
5 Years
69.31%
0%
69.31%

Alnylam Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
49.77%
EBIT Growth (5y)
21.11%
EBIT to Interest (avg)
-3.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
118
Industry P/E
Price to Book Value
53.33
EV to EBIT
83.59
EV to EBITDA
75.24
EV to Capital Employed
67.14
EV to Sales
11.29
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
80.33%
ROE (Latest)
45.14%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 133 Schemes (58.0%)

Foreign Institutions

Held by 421 Foreign Institutions (20.44%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6.40% vs -12.17% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 10.52% vs -25.77% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,167.20",
          "val2": "1,097.00",
          "chgp": "6.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "282.20",
          "val2": "145.20",
          "chgp": "94.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "69.30",
          "val2": "129.30",
          "chgp": "-46.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "135.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "206.00",
          "val2": "186.40",
          "chgp": "10.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "230.20%",
          "val2": "120.10%",
          "chgp": "11.01%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 65.19% vs 22.97% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 212.76% vs 36.80% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,713.90",
          "val2": "2,248.20",
          "chgp": "65.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "557.20",
          "val2": "-120.20",
          "chgp": "563.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "252.60",
          "val2": "141.90",
          "chgp": "78.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-42.50",
          "val2": "-170.80",
          "chgp": "75.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "313.70",
          "val2": "-278.20",
          "chgp": "212.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "135.10%",
          "val2": "-78.70%",
          "chgp": "21.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
1,167.20
1,097.00
6.40%
Operating Profit (PBDIT) excl Other Income
282.20
145.20
94.35%
Interest
69.30
129.30
-46.40%
Exceptional Items
0.00
135.50
-100.00%
Consolidate Net Profit
206.00
186.40
10.52%
Operating Profit Margin (Excl OI)
230.20%
120.10%
11.01%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 6.40% vs -12.17% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 10.52% vs -25.77% in Dec 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
3,713.90
2,248.20
65.19%
Operating Profit (PBDIT) excl Other Income
557.20
-120.20
563.56%
Interest
252.60
141.90
78.01%
Exceptional Items
-42.50
-170.80
75.12%
Consolidate Net Profit
313.70
-278.20
212.76%
Operating Profit Margin (Excl OI)
135.10%
-78.70%
21.38%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 65.19% vs 22.97% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 212.76% vs 36.80% in Dec 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Alnylam Pharmaceuticals, Inc. stock-summary
stock-summary
Alnylam Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.
Company Coordinates stock-summary
Company Details
675 W Kendall St , CAMBRIDGE MA : 02142-1168
stock-summary
Tel: 1 617 5518200
stock-summary
https://www.alnylam.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."